
Opthea (OPT) Stock Forecast & Price Target
Opthea (OPT) Analyst Ratings
Bulls say
Opthea Ltd is focused on developing innovative biologic therapies for eye diseases, particularly through its lead product, OPT-302, which targets Vascular Endothelial Growth Factors C and D. Positive results from its Phase 3 COAST trial, anticipating improvements in best-corrected visual acuity (BCVA) of 3 to 5 letters, suggest strong potential for adoption among retinal specialists and broad coverage from payers. The company's early trial data indicates meaningful advancements in visual acuity compared to standard therapies, supporting a favorable outlook for future commercial success.
Bears say
Opthea Ltd reported a substantial net loss of $131.9 million, equating to $0.11 per share for the first half of FY 2025, indicating significant challenges in achieving financial viability. The company faces considerable risks that could impair its ability to reach peak commercial revenue estimates for its investigational product, OPT-302, largely influenced by market size, penetration rates, and pricing strategies. Furthermore, potential difficulties in securing necessary capital resources and ongoing challenges in program development and commercialization further contribute to a negative outlook for the company's financial stability.
This aggregate rating is based on analysts' research of Opthea and is not a guaranteed prediction by Public.com or investment advice.
Opthea (OPT) Analyst Forecast & Price Prediction
Start investing in Opthea (OPT)
Order type
Buy in
Order amount
Est. shares
0 shares